Efanesoctocog alfa for long-term joint health in hemophilia A
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Genetic & congenital clinical trials.
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate or severe hemophilia A (factor VIII level 5% or less).
- You do not have an inhibitor (antibody that blocks treatment) now or in the past 3 years.
- You are starting efanesoctocog alfa (a new factor VIII medicine) for the first time within the last 3 months.
- You are able to have MRI scans and joint exams (with sedation for kids if needed).
- Your doctor has already decided to prescribe efanesoctocog alfa before you join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study looks at how safe and effective Octocog alfa (a Factor VIII medicine) is for treating sudden bleeds in adults with severe hemophilia A in India. It is for people who already have experience with Factor VIII products and are not on regular preventive treatment.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.